(NASDAQ: AVLN) Avalyn Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.85%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.68%.
Avalyn Pharma's earnings in 2026 is N/A.On average, 7 Wall Street analysts forecast AVLN's earnings for 2026 to be -$148,139,037, with the lowest AVLN earnings forecast at -$169,441,089, and the highest AVLN earnings forecast at -$125,218,827. On average, 7 Wall Street analysts forecast AVLN's earnings for 2027 to be -$133,850,480, with the lowest AVLN earnings forecast at -$176,392,518, and the highest AVLN earnings forecast at -$96,823,479.
In 2028, AVLN is forecast to generate -$136,111,468 in earnings, with the lowest earnings forecast at -$196,377,878 and the highest earnings forecast at -$98,685,469.